Evaluation and Management of Microscopic Hematuria

Introduction to Microscopic Hematuria

Microscopic hematuria is definitively diagnosed at ≥3 RBCs/HPF, and this patient's count substantially exceeds that threshold 1, 2
The American Urological Association (AUA) and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) guidelines stratify risk partly based on RBC count (3-10 RBCs/HPF being low risk, with higher counts conferring increased risk) 1
Age is a critical risk factor: males ≥60 years are classified as high-risk and require cystoscopy and CT urography regardless of other factors; males 40-59 years are intermediate-risk 1

The degree of hematuria places the patient in a higher risk category for underlying pathology 1
Malignancy, such as bladder cancer, renal cell carcinoma, or urothelial carcinoma, accounts for 2.6-4% of microscopic hematuria cases, with risk increasing substantially with age >35-40 years and male gender 1, 2

Confirm microscopic hematuria with ≥3 RBCs/HPF on at least two of three properly collected clean-catch midstream specimens 1, 2
Examine urinary sediment for dysmorphic RBCs (>80% suggests glomerular origin) and red cell casts (pathognomonic for glomerular disease) 1, 2
Assess for proteinuria using spot urine protein-to-creatinine ratio (normal <0.2 g/g), as significant proteinuria indicates renal parenchymal disease 1, 2
Measure serum creatinine and eGFR to assess renal function; elevated creatinine suggests renal parenchymal disease 1, 2

Multiphasic CT urography is the preferred imaging modality to identify hydronephrosis, urinary calculi, and renal/ureteral lesions 1, 2, 3
Cystoscopy is mandatory for all patients ≥35 years old to evaluate for bladder masses, urethral stricture disease, and benign prostatic hyperplasia 1, 2, 3
Flexible cystoscopy is preferred over rigid cystoscopy as it causes less pain and has equivalent or superior diagnostic accuracy 1, 3

Complete urologic evaluation is mandatory for patients with microscopic hematuria, including multiphasic CT urography and cystoscopy 1, 2
Immediate nephrology referral is warranted for concurrent evaluation if features suggest glomerular origin (>80% dysmorphic RBCs, RBC casts, significant proteinuria, elevated creatinine) 1, 2, 3
Quantify proteinuria with spot urine protein-to-creatinine ratio or 24-hour collection, and complete metabolic panel including serum creatinine, BUN, albumin, and total protein 1, 3

Repeat urinalysis, blood pressure measurement, and assessment for proteinuria at 6, 12, 24, and 36 months if the complete urologic evaluation is negative 1, 2
Consider repeat anatomic evaluation (imaging and/or cystoscopy) within 3-5 years if hematuria persists or recurs 2, 3
Immediate re-evaluation is warranted if gross hematuria develops, significant increase in microscopic hematuria occurs, new urologic symptoms appear, or development of hypertension/proteinuria 1, 3

Microscopic hematuria is defined as the presence of ≥ 3 red blood cells per high‑power field (RBC/HPF) on microscopic examination of a properly collected urine specimen. This threshold is used to determine when further urologic evaluation is warranted. 4

The American Urological Association (AUA) and Society of Urologic Oncology (SUFO) guidelines require laboratories to report urinary RBC counts quantitatively (cells/L or cells/mL) so clinicians can assess whether the count meets or exceeds the ≥ 3 RBC/HPF threshold and decide on additional work‑up. 4

A positive urine dipstick for blood (trace or greater) is insufficient by itself to define microscopic hematuria; it should prompt a formal microscopic urinalysis to confirm ≥ 3 RBC/HPF before any diagnostic pathway is initiated. 4
Microscopic confirmation of ≥ 3 RBC/HPF on a properly collected specimen is mandatory prior to starting any urologic work‑up. 4

Clinicians should not rely solely on the presence of anticoagulant or antiplatelet therapy as an explanation for hematuria; these agents may unmask underlying disease but do not obviate the need for evaluation. 4
Patients receiving anticoagulants should be assessed in the same manner as non‑anticoagulated patients, because their risk of underlying malignancy is comparable to the general hematuria population. 4

After confirming microscopic hematuria, clinicians should stratify risk based on age, smoking history, occupational exposures, and irritative voiding symptoms to determine the intensity of the diagnostic work‑up. 4